Seelos Therapeutics (DB:NXE0) - Hisse Senedi Fiyatı, Haberler ve Analizler

NXE0 Stoklara Genel Bakış

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders.

Şirket hakkında

NXE0 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Hisse senetleri oldukça likit değildir

Kazançlar son 5 yılda yılda 13.1% oranında azaldı

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Anlamlı bir piyasa değeri yok ( €727K )

+ 2 daha fazla risk

Seelos Therapeutics, Inc. Rakipler

MPH Health Care

DB:93M1

€101.0m

SciSparc

NasdaqCM:SPRC

US$758.2k

Biofrontera

XTRA:B8FK

€17.5m

Resonate Blends

OTCPK:KOAN

US$642.6k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Seelos Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.00
52 Haftanın En Yüksek Seviyesi	US$288.96
52 Haftanın En Düşük Seviyesi	US$2.00
Beta	1.89
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-99.31%
33 Yıllık Değişim	-99.50%
5 Yıllık Değişim	-99.43%
Halka arzdan bu yana değişim	-99.76%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	NXE0	DE Pharmaceuticals	DE Pazar
7D	0%	-2.4%	-2.2%
1Y	-99.3%	-13.3%	13.3%

Getiri vs. Endüstri: NXE0 geçen yıl % -13.3 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: NXE0 geçen yıl % 13.3 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NXE0's price volatile compared to industry and market?
NXE0 volatility
NXE0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: NXE0 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: NXE0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2016	10	Raj Mehra	seelostherapeutics.com

Seelos Therapeutics, Inc. Temel Bilgiler Özeti

Seelos Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NXE0 temel i̇stati̇sti̇kler
Piyasa değeri	€665.26k
Kazançlar(TTM)	-€24.82m
Gelir(TTM)	€1.81m

0.4x

P/S Oranı

0.0x

F/K Oranı

NXE0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NXE0 gelir tablosu (TTM)
Gelir	US$1.97m
Gelir Maliyeti	US$27.97m
Brüt Kâr	-US$26.00m
Diğer Giderler	US$1.12m
Kazançlar	-US$27.11m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-9.48
Brüt Marj	-1,317.12%
Net Kâr Marjı	-1,373.61%
Borç/Özkaynak Oranı	-39.5%

NXE0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NXE0 Stoklara Genel Bakış

Ödüller

Risk Analizi

Seelos Therapeutics, Inc. Rakipler

DB:93M1

€101.0m

NasdaqCM:SPRC

US$758.2k

XTRA:B8FK

€17.5m

OTCPK:KOAN

US$642.6k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Recent updates

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Founder recently bought €92k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought €51k worth of stock

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

New 90-day high: €3.20

New 90-day high: €1.60

Seelos Therapeutics, Inc. Announces Dosing of the First Patients in its Registrational Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior

Seelos Therapeutics Regains Compliance with Minimum Bid Price Requirement

New 90-day high: €1.33

Seelos Therapeutics, Inc. announced that it has received $10 million in funding from The Lind Partners, LLC

New 90-day high: €0.93

Revenue in line with expectations

Seelos Therapeutics, Inc. Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.00335 million.

New 90-day low - €0.56

New 90-day low - €0.70

Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from Russell Microcap Value Index